Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34(+) blood cells to pre-empt relapse in patients with CD34(+) myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Platzbecker, U, Wermke, M, Radke, J, Oelschlaegel, U, Seltmann, F, Kiani, A, Klut, I-M, Knoth, H, Röllig, C, Schetelig, J, Mohr, B, Graehlert, X, Ehninger, G, Bornhäuser, M, Thiede, C
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Leading Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306138/
https://ncbi.nlm.nih.gov/pubmed/21886171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.234
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars